Jefferies Financial Group Inc. Exelixis, Inc. Transaction History

Jefferies Financial Group Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$20.34 - $23.73 $3.26 Million - $3.8 Million	-160,200 Reduced 86.04%	26,000 $584,000
Q1 2024 May 13, 2024	BUY	$20.17 - $23.93 $530,834 - $629,789	26,318 Added 16.46%	186,200 $4.42 Million
Q4 2023 Feb 13, 2024	SELL	$19.25 - $24.13 $9,971 - $12,499	-518 Reduced 0.32%	159,882 $3.84 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $2.92 Million - $3.49 Million	153,400 Added 2191.43%	160,400 $3.5 Million
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $463,335 - $522,240	-25,500 Reduced 78.46%	7,000 $133,000
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $13,007 - $15,489	-798 Reduced 2.4%	32,500 $630,000
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $498,138 - $579,052	33,298 New	33,298 $534,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.